What is Survodutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Video overview · 3:14
Survodutide: The GLP-1 + Glucagon Drug for Weight Loss and Fatty Liver. What the Trials Show
How the glucagon half is supposed to help, the phase 2 and SYNCHRONIZE phase 3 weight-loss results, the liver trials, the high rate of people stopping because of side effects, and where it stands with regulators.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Survodutide is an experimental drug for obesity and fatty liver disease that hits two hormone targets: GLP-1, like Ozempic, and glucagon. It has now finished its first big obesity trials. Here's what they show, and why the side effects matter.
Survodutide was discovered by Zealand Pharma and is developed by Boehringer Ingelheim. It activates two receptors: GLP-1, which cuts appetite, and glucagon, which is thought to raise energy use and change how the liver handles fat. In trials, it's a weekly injection, tested for both obesity and fatty liver disease.
Here's the idea. The GLP-1 side lowers appetite. The glucagon side is proposed to burn more energy and clear fat from the liver. Together, they produced weight loss in trials. Whether that beats semaglutide in a large head-to-head trial hasn't been tested.
In the phase 2 obesity trial, 387 adults lost about six to fifteen percent over 46 weeks, versus about three on placebo. The often-quoted nineteen percent counts only people who stayed on the top dose. In phase 3, SYNCHRONIZE-1 found about twelve to thirteen percent over 76 weeks, versus about five on placebo. In people with type 2 diabetes, it was eight to ten percent, versus four.
The liver results drew the most attention. In a phase 2 trial of 293 adults with biopsy-confirmed fatty liver disease, called MASH, the disease improved without worse scarring in up to sixty-two percent, versus fourteen on placebo. The FDA gave it breakthrough therapy status for MASH in 2024. The phase 3 liver trials are still recruiting.
The catch is tolerability. In SYNCHRONIZE-1, stomach and gut side effects hit eighty to ninety percent of people, versus about half on placebo, and about one in five stopped because of them, versus three percent on placebo. In the phase 2 obesity trial, about one in four stopped because of side effects.
Survodutide is not approved anywhere, and Boehringer hasn't announced filing plans. A heart-safety trial finished in 2026, with results not yet posted. A rival GLP-1 and glucagon drug, mazdutide, was approved in China in 2025. And the FDA has warned companies selling survodutide falsely labeled for research.
Does survodutide beat semaglutide? Unproven: there's no phase 3 head-to-head. Does it treat fatty liver disease? Limited: a strong phase 2 result, with phase 3 still recruiting. Is it approved? No. And are research vials the trial drug? No: the FDA calls them falsely labeled, unapproved products.
The bottom line: survodutide produced about twelve to thirteen percent weight loss in its first big trial, and a striking phase 2 liver result. But about one in five people stopped because of side effects, and it isn't approved anywhere. For every study and source, see the survodutide profile on PepsRadar dot com.
Biological role or research focus
Obesity research.
The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Role reference: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Names you may encounter
BI 456906
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Dual GLP-1 / glucagon receptor agonist
- Research focus
- Obesity research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Quick answers
- Is Survodutide FDA approved?
- No. No FDA-approved drug contains Survodutide. Source ↗
- Is Survodutide safe?
- Investigational GLP-1/glucagon drug, not FDA-approved. Trials report very frequent nausea, vomiting and diarrhea; long-term and rare risks are not yet known. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Survodutide banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over Survodutide?
- Yes. Our records list 3 FDA actions naming it, most recently on October 1, 2026: FDA states it has warned companies illegally selling unapproved drugs containing survodutide (and other GLP-1 agents) falsely labeled "for research purposes." Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| SYNCHRONIZE-1 (2026) | Human randomized trial | 725 adults without diabetes who had obesity, or overweight with an associated condition. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2026
SYNCHRONIZE-1
How did weight change over 76 weeks?
- Population / model
- 725 adults without diabetes who had obesity, or overweight with an associated condition.
- Study design
- Double-blind randomized phase 3 trial, two survodutide groups versus placebo, with lifestyle counseling over 76 weeks.
- Main finding
- Mean weight changes in the treatment-regimen analysis were −12.2% and −13.0% versus −5.4% with placebo. Gastrointestinal adverse events occurred in 80.9%, 89.7%, and 47.9%, respectively.
- Limits & context
- The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
36 registered studies name Survodutide as an intervention; 7 are recruiting or under way, 4 have not started recruiting yet and 25 completed. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 36 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. ↗
Diabetes care · 2024 Nov 1 · Journal Article, Review, Research Support, Non-U.S. Gov't
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. ↗
Hepatology (Baltimore, Md.) · 2025 Dec 1 · Journal Article, Systematic Review, Comparative Study, Network Meta-Analysis, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Read available full text ↗
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. ↗
Alimentary pharmacology & therapeutics · 2025 Jun · Journal Article, Review
Read available full text ↗
Weight management treatment in obesity. ↗
Medicina clinica · 2025 Nov · Journal Article, Review
Risks & interactions
Investigational GLP-1/glucagon drug, not FDA-approved. Trials report very frequent nausea, vomiting and diarrhea; long-term and rare risks are not yet known.
Phase 2 and 76-week phase 3 trials report digestive side effects in about 73-90% of participants vs 39-48% on placebo, mostly mild to moderate. Serious events were similar to placebo in a liver trial. Heart and long-term outcomes are still under study.
Warnings for approved drugs in the same class (semaglutide, tirzepatide, liraglutide, dulaglutide), which may apply here too: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problemsBlood thinners or bleeding problemsHeart or blood pressure problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Interactions
- Anesthesia or sedation: GLP-1-based medicines slow stomach emptying, and reviews flag retained stomach contents as a class concern
Serious risks
- Pancreas and gallbladder problems are discussed as safety concerns for GLP-1-based medicines as a class
- FDA warns that survodutide sold 'for research purposes' is unapproved and of unknown quality
Side effects reported in studies
- nausea
- diarrhea
- vomiting
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: SYNCHRONIZE-1: survodutide for obesity (N Engl J Med, 2026) ↗ · Survodutide in obesity and type 2 diabetes (N Engl J Med, 2026) ↗ · Phase 2 trial of survodutide in MASH and fibrosis (2024) ↗ · Efficacy and safety of GLP-1 medicines (review) ↗ · FDA: Concerns with unapproved GLP-1 drugs ↗
What the featured evidence can tell us
Gastrointestinal events were substantially more frequent in the active-treatment groups. The absence of reported deaths in this trial cannot establish absence of rare serious harms.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Identity, route, and evidence limits
The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- FDA states it has warned companies illegally selling unapproved drugs containing survodutide (and other GLP-1 agents) falsely labeled "for research purposes." (2026-10-01) source
- FDA warning letter to a "research peptide" seller (NuScience Peptides) naming "Survodutide", mazdutide, retatrutide and other peptides as unapproved new drugs. (2026-08-24) source
- FDA warning letter to a "research peptide" seller (Xcel Research) naming "SURVODUTIDE", retatrutide and others as unapproved new drugs despite research-use-only labeling. (2024-12-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
The selected publication describes investigational treatment in obesity research. It does not establish the identity, effectiveness, or safety of a seller’s research vial.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
How Survodutide works
It engages GLP-1 and glucagon receptor pathways. The relevant evidence is the balance of measured weight outcomes and harms, rather than a presumed benefit from engaging two receptors.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Molecular structure
Questions worth asking
- Why does the analysis method matter?
- What population, comparator, and route were actually studied?
- The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Why does the analysis method matter?
An analysis that includes discontinuation answers a different question from one estimating outcomes if everyone remained on treatment. Read the population and estimand before comparing percentages.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
